CSIMarket


Tcr2 Therapeutics Inc   (TCRR)
Other Ticker:  
 


 

Tcr2 Therapeutics Inc

TCRR's Financial Statements and Analysis



Tcr2 Therapeutics Inc increased first quarter of 2023 net loss per share of $-1.03 compare to net loss per share of $-0.76 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.54 realized in previous quarter.


first quarter of 2023
Earnings Per Share Revenues
$ -1.03 $  0 Mill
$-0.27     Unch.    



Tcr2 Therapeutics Inc 's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.


Tcr2 Therapeutics Inc is Expected to report next financial results on March 22, 2024.

More on TCRR's Income Statement



Tcr2 Therapeutics Inc 's in thefirst quarter of 2023 recorded net loss of $-40.399 million, an increase from net loss of $-29.122 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-60.505 million realized in previous quarter.

More on TCRR's Growth

Tcr2 Therapeutics Inc Inventories
In Mar 31 2023 company's net cash and cash equivalents decreased by $-18 million, capital expenditures grew by -1.977-92.01%, to $0 millions compare to same quarter a year ago

More on TCRR's Cash flow Statement


Tcr2 Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Tcr2 Therapeutics Inc payed $ -2.81 cash per share, on a free-cash flow basis .

Book value fell by -29.14 % sequentially to $2.58 per share, -25.41% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.58 per share from $ 3.65.

Company issued 0.59 million shares or 1.53 % in Mar 31 2023.


More on TCRR's Dividends

 Market Capitalization (Millions) 62
 Shares Outstanding (Millions) 39
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -163
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) -14
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Tcr2 Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Tcr2 Therapeutics Inc had negative $ -2.81 cash flow per share, on a free-cash flow basis .

Book value fell by -29.14 % sequentially to $2.58 per share, -25.41% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.58 per share from $ 3.65.

Company issued 0.59 million shares or 1.53 % in Mar 31 2023.


More on TCRR's Balance Sheets

 Market Capitalization (Millions) 62
 Shares Outstanding (Millions) 39
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -163
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) -14
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Tcr2 Therapeutics Inc Earnings

TCRR's Rising Expenses Threaten Long-Term Viability, Tcr2 Therapeutics Inc Reports Significant Q1 Shortfall

As the Biotechnology a...


Date modified: 2023-05-14T14:04:01+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com